ATXI Key Statistics, Chart & Performance
The current stock price of ATXI is 0.42 USD. In the past month the price decreased by -69.78%. In the past year, price decreased by -96.3%.
ATXI Technical Analysis
ATXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATXI. The financial health of ATXI is average, but there are quite some concerns on its profitability.
ATXI Financial Highlights
Over the last trailing twelve months ATXI reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 83.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| Debt/Equity | 0 |
ATXI Forecast & Estimates
7 analysts have analysed ATXI and the average price target is 8.16 USD. This implies a price increase of 1842.86% is expected in the next year compared to the current price of 0.42.
ATXI Ownership
ATXI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.99 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.57 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.11 | 293.697B | ||
| PFE | PFIZER INC | 8.9 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.81 | 117.3B | ||
| ZTS | ZOETIS INC | 18.47 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.44 | 25.214B | ||
| VTRS | VIATRIS INC | 5.65 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.07 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 222.12 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATXI
Company Profile
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Company Info
AVENUE THERAPEUTICS INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10036 US
CEO: Lucy Lu
Employees: 3
Phone: 17816524500
AVENUE THERAPEUTICS INC / ATXI FAQ
What does AVENUE THERAPEUTICS INC do?
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
What is the current price of ATXI stock?
The current stock price of ATXI is 0.42 USD. The price decreased by -50.71% in the last trading session.
Does ATXI stock pay dividends?
ATXI does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATXI stock?
ATXI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ATXI stock?
AVENUE THERAPEUTICS INC (ATXI) operates in the Health Care sector and the Pharmaceuticals industry.
Who owns AVENUE THERAPEUTICS INC?
You can find the ownership structure of AVENUE THERAPEUTICS INC (ATXI) on the Ownership tab.
What is the outstanding short interest for AVENUE THERAPEUTICS INC?
The outstanding short interest for AVENUE THERAPEUTICS INC (ATXI) is 0% of its float.